Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

Erleada

,

Reporting on Apalutamide (Erleada) for Castrate Sensitive Prostate Cancer

,

The use of apalutamide (Erleada) improved radiographic progression-free survival with a 52% reduction in risk of death or radiographic progression; that benefit was observed across all subgroups analyzed in the TITAN TRIAL for men with progressing prostate cancer that is still hormone sensitive. The median radiographic progression-free survival was not reached in the apalutamide group and was 22.1 months in the placebo group.

,

Announcing an Educational Webinar About Erleada

,

Jansen Pharmaceuticals has requested that we let our blog readers know about an upcoming educational webinar they are sponsoring on Tuesday, 9/18/18, 7 p.m. ET.  The webinar will be discussing their newly approved treatment, apalutamide (Erleada) which is approved by the FDA for men with castrate resistant, non-metastatic prostate cancer, sometimes referred to as M0 (M-zero) disease.  

, , ,

A New Drug Approval- Erleada ™ (apalutamide) For Non-Metastatic Castration-Resistant Prostate Cancer

, , ,

he FDA approved a new advanced hormone therapy drug (a next-generation androgen receptor inhibitor) for the treatment of men with non-metastatic castration-resistant prostate cancer (NM-CRPC). This drug with the trade name Erleada (aka apalutamide), is the first drug approved in this disease space. 

Gold Guidestar Seal
Gold Transparency 2022